| Name | Ginkgolide B |
| Description | Ginkgolide B (BN-52021) is a PAFR antagonist(IC50=3.6 μM) isolated from Ginkgo biloba. |
| In vitro | Oral administration of Ginkgolide B (50 mg/kg) before ischemia notably reduces neuronal damage in the hippocampus of rats. In a mouse model of focal transient ischemia, a 30-minute pretreatment with Ginkgolide B (100 mg/kg, s.c.) diminishes the area of infarction. Additionally, in animals anesthetized with pentobarbital or ethyl carbamate, Ginkgolide B, administered either intravenously (1 mg/kg) or orally (10 mg/kg), inhibits bronchoconstriction and increases hematocrit. |
| In vivo | Ginkgolide B effectively inhibits platelet-activating factor (PAF) receptors. In cystic cells, it modifies the Ras/MAPK signaling pathway, inducing cell differentiation. In EPC cells, Ginkgolide B promotes cell proliferation and endothelial gene expression by inducing the phosphorylation of eNOS, Akt, and p38, significantly enhancing vascular endothelial growth factor (VEGF)-induced migration responses. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (141.38 mM)
Ethanol : 10.6 mg/mL (25 mM)
|
| Keywords | BN52021 | Apoptosis | inhibit | Ginkgolide B | Inhibitor | BN 52021 | Endogenous Metabolite |
| Inhibitors Related | Stavudine | Potassium gluconate | 5-Fluorouracil | Dextran sulfate sodium salt (MW 4500-5500) | Sodium 4-phenylbutyrate | Acetaminophen | Sorafenib | Tributyrin | Formamide | Oleamide | Glycerol | Oleic acid |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Terpene Natural Product Library | Bioactive Compound Library | Flavor Compound Library | Selected Plant-Sourced Compound Library | Inhibitor Library | Natural Product Library for HTS | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Food as Medicine Compound Library |
United States
